Small Caps Stocks for September

Valeant Pharmaceuticals International (NYSE: VRX) develops drugs used to fight epilepsy, Parkinson’s disease, migraines, acne and even skin cancer. In August, VRX announced outstanding earnings for the second quarter including profit of $57.1 million, or $0.69 per share, compared with $0.52 per share in the second quarter of last year. Additionally, the company reported sales of $255.6 million compared with sales of $191.7 million in 2009. Those numbers tally out to a +9.5% earnings surprise and a +6.9% sales surprise!

VRX also recently received preliminary approval by the FDA for a new anti-seizure medications it is developing in conjunction with GlaxoSmithKline (NYSE: GSK). That paints a bright picture for the future of Valeant.